MIST: Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for MIST
Across the 5 sessions after earlier MIST headlines, the stock closed higher 1 times and lower 4 times, with a median move of 2.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MIST | SPY |
|---|---|---|---|
| Dec 15, 2025 | Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | -2.7% | -0.2% |
| Dec 3, 2025 | Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.1% | +0.3% |
| Nov 12, 2025 | Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | +1.0% | +0.1% |
| Nov 5, 2025 | Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.2% | +0.3% |
| Nov 3, 2025 | Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 | -3.6% | +0.2% |
Quantisnow market dataNASDAQ
MIST
Milestone Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for MIST
Full MIST profile on Quantisnow Follow MIST and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time